key: cord-0310057-qawif39o authors: Liley, J.; Bohner, G.; Emerson, S. R.; Mateen, B. A.; Borland, K.; Carr, D.; Heald, S.; Oduro, S. D.; Ireland, J.; Moffat, K.; Porteous, R.; Riddell, S.; Cunningham, N.; Holmes, C.; Payne, K.; Vollmer, S. J.; Vallejos, C. A.; Aslett, L. J. M. title: Development and assessment of a machine learning tool for predicting emergency admission in Scotland date: 2021-08-10 journal: nan DOI: 10.1101/2021.08.06.21261593 sha: 394dcb21edcd9526fea59e6555dcfb771e1ff0f3 doc_id: 310057 cord_uid: qawif39o Avoiding emergency hospital admission (EA) is advantageous to individual health and the healthcare system. We develop a statistical model estimating risk of EA for most of the Scottish population (>4.8M individuals) using electronic health records, such as hospital episodes and prescribing activity. We demonstrate good predictive accuracy (AUROC 0.80), calibration and temporal stability. We find strong prediction of respiratory and metabolic EA, show a substantial risk contribution from socioeconomic decile, and highlight an important problem in model updating. Our work constitutes a rare example of a population-scale machine learning score to be deployed in a healthcare setting. higher AUPRC) and slightly attenuated calibration (Figure 2c) . A density plot of v3 and v4 scores is shown in Supplementary figure 5 . The performance of v4 may attenuate in a healthcare system where v3 is not in use [27, 18, 19] . We found that the difference in performance (by AUROC) between v3 and v4 was higher in subcohorts of patients at high risk (age > 80) and at low risk (age 20 − 70, no previous EA), with a smaller performance differential in the complement of these subcohorts (denoted as moderate risk, Figures 2f, 2g, 2h) . In high-and low-risk cohorts, general predictive accuracy (rather than differential) was lower than for the whole cohort (AUROC ≈ 0.7 for high-and low-risk subcohorts), suggesting that the differential performance of v4 was driven by improved performance on difficult-to-predict high-and low-risk samples, with more equivalent performance on easy-to-predict moderate-risk samples. In individuals for which v3 and v4 disagreed (|v3 − v4| > 0.1), we found that v4 was better-calibrated when v4 > v3 and equivocal to v3 when v3 > v4 (Figure 2i ). To examine differences in performance more closely, we next explored the performance of SPARRA v3 and SPARRA v4 across different patient subcohorts defined by age, SIMD deciles and the three subcohorts defined as part of SPARRA v3 development. We noted that our model outperformed the existing score in terms of AUROC over all subcohorts (Figure 3a-c) . We also explored the performance of SPARRA v4 after stratifying different types of EA admissions. We found that our model was able to predict certain medical classes of admission disproportionately well (Figures 3d,3e) , namely predicting respiratory and endocrine/metabolic related admissions. As expected, we were less able to predict traumatic admissions, and admissions due to external causes of morbidity (ICD codes V00-Y99 [24] ). Supplementary figure 10 shows relative performance by type of admission (injury, referral etc), with slightly better performance for non-injury-related than injury-related admissions. When further analysing the risk scores predicted by SPARRA v4, we found that our model tends to better predict imminent admissions: individuals with high risk scores were more likely to have an EA near the start of the 1 year outcome period ( Figure 3f ). This was partly because individuals with a high risk score were disproportionately more likely to have multiple admissions ( Figure 3g ). However, amongst those with only one admission, individuals with a high SPARRA v4 score were also more likely to have an admission earlier in the year (Figure 3h ). Using the same analysis pipeline as for SPARRA v4, we fitted a model M 0 to an early time cutoff (t 0 =1 May 2014), using only one year of data to derive predictors. We then assembled test matrices from data 1 year prior to the time points t 1 =1 May 2015, t 2 =1 Dec 2015, t 3 =1 May 2016, t 4 =1 Dec 2016, and t 5 =1 May 2017 and applied M 0 to predict EA in the year following each time point. This enabled assessment of how the performance of M 0 changed over time. In order to ensure a fair comparison, we compared performance on subsamples of 1 million individuals from time points t 1 − t 5 chosen such that global admission rates matched those at t 0 . We found that M 0 performed essentially equally well when used to predict admission following t 1 − t 5 , with no statistically significant decrease in performance (adjusted p-values > 0.05 or improved performance with time for all comparisons of AUROCs; Supplementary Figures 6a, 6c, 6b) . We then compared how well fixed predictions computed at t 0 performed over time. We subsampled individuals with complete data such that admission rates and age distributions at t 1 − t 5 matched those at t 0 , and assessed how well the initial scores predicted EA subsequent to t 1 − t 5 . We observed that the fixed scores performed reasonably well even 2-3 years after t 0 , although calibration was gradually lost (Figures 4a, 4b, 4c ). We also note that the fixed scores obtained at t 0 predicted the event 'any EA between t 1 and a year after t 5 ' with AUROC 0.84 (SE < 4 × 10 −4 ), higher than that achievable for predicting EA in one year periods. More generally, we observe that scores fitted and calculated at a fixed timepoint had successively lower AUROCs for predicting EA over future periods (Supplementary figure 8) . We then considered how individual scores changed amongst all patients with complete data at all time periods. We found that while quantiles of the distribution of scores at t 1 − t 5 increased as the cohort grew older (Figure 4d ), the mean risk scores of individuals in the highest centiles of risk at t 0 tended to decrease over time (Figure 4e ), suggesting that very high risk scores tend to be transient. We analysed this more closely by comparing bivariate densities of scores (Figure 4f and Supplementary Figure 7 ). We found that lower scores are more stable than higher scores over subsequent time points, and individuals 'jump' to higher scores (upper left in Figure 4f ) more than they drop to lower scores (bottom right). Amongst individuals with a given score at t 1 , median score at t 2 tends to be lower, although quantiles of the overall score distribution increase (Figures 4d and 4e ). We examined the contribution of predictors to risk scores at an individual level by estimating Shapley values [20] for each predictor/individual pair. The predictors with largest mean absolute Shapley value (excluding v3 and topic features) were age, the number of recorded long-term conditions, the number of previous A&E attendances, and the number of previous EAs (Table 5e ). Most predictors had non-linear effects (Supplementary Figures 14-20) . We found a non-linear importance of age: the risk contribution from age was high in infancy, dropped rapidly through childhood, remained stable until around age 65, then rose rapidly, stabilising at around age 75 until death (Figure 5a) . We also found a non-linear importance of SIMD [13] (Figure 5b ) and number of previous emergency hospital admissions (Supplementary Figure 13) . We further investigated the contribution of SIMD by comparing Shapley values between variables. We computed the mean difference in contribution of SIMD to risk score between individuals in SIMD 10 areas (lowest deprivation) and SIMD 1 areas (highest deprivation), and the additional years of age which would contribute an equivalent amount. This was generally around 10-40 additional years (Figure 5c ). In terms of raw admission rates, disparity was further apparent: individuals aged 20 in SIMD 1 areas had similar admission rates to individuals aged 70 in SIMD 8-10 areas (Figure 5d ). We assessed the added value of inclusion of topic-model derived features, which summarise more granular information about the previous medical history of a patient with respect to those included in SPARRA v3. For this purpose, we refitted model M 0 with topic-derived features excluded from the predictor matrix (model M 0 ). We compared the performance of M 0 and M 0 on a set of test data for time point t 1 . On comparison of AUROC curves, M 0 had a slightly better performance than M 0 , though the absolute AUROC difference was small (p-value = 6 × 10 −47 ; AUC 0.789 vs 0.788; Supplementary figure 12). Analogously to Figure 2 , we also computed the additional number of samples correctly identified as having an EA amongst the top scores by M 0 and M 0 , and found that use of M 0 over M 0 increased the number of EAs detected in the top 500,000 scores by around 200. Supplementary table 4 shows the most pertinent features (ICD10 codes and prescription types) for each topic in the model used for prediction on fold 1. Finally, we explored a breakdown of model performance (AUROCs, AUPRCs, and calibration curves) across the different model constituents included in our ensemble (Table 3, Figures 2, 3 , and 4). The performance of the ensemble was slightly better than the best constituent models (XG-boosted trees and random forests). Several constituent models (ANN, GLM, Naive Bayes) had vanishing coefficients in all ensembles, so predictions for these models need not be computed when generating SPARRA v4. The SPARRA v4 model is a state-of-the-art risk prediction model for EA developed using routinely collected EHR data, optimised for use in the Scottish population. It augments and consistently outperforms the SPARRA v3 model that is currently in clinical use. Although the improvement on model metrics (AUROC, AUPRC) from SPARRA v3 to SPARRA v4 is small, this difference is highly meaningful in terms of absolute performance. More generally, we demonstrate that sophisticated machine learning methods can enable meaningful gains in performance in a real-world setting. In particular, to our knowledge, this is the first use of a topic model to summarise complex multi-morbidity data (captured by historic prescriptions and diagnosis) and an ensemble prediction approach in the context of EA prediction. We highlight a hazard of updating widely-circulated predictive scores, and discuss how machine leaning models can be deployed, an area of growing importance for health data science. We find a range of epidemiological associations with predictable EA risk. Both the tendency to predict imminent admissions and the relative instability of high risk scores with time indicate that SPARRA v4 is sensitive to short-term periods of high risk, particularly relating to respiratory, metabolic and mental-health related illness. The relationship between deprivation (SIMD) and EA risk is complex; SIMD includes a constituent of general health [13] , and individuals in low-SIMD areas are more likely to miss primary care appointments [12] suggesting a lower overall rate of primary care uptake. We do not assert causality for this or any other reported associations. In particular, we cannot make counterfactual predictions, and thus cannot directly recommend any changes to patient management which would lower EA risk. Furthermore, lowering of EA risk does not necessarily entail overall patient benefit. : for instance, long-term oral corticosteroid use in mild asthmatics would reduce EA risk at an unacceptable cost of long-term morbidity. actions taken to stabilise at-risk patients As such, any potential interventions should be carefully assessed by GPs and other members of the clinical team on a case-by-case basis. We chose to code our target variable as EA in the subsequent year. This is not a universal choice in EA prediction [25, 30] , and targets such as survival time to admission may lead to different model properties and performance (noting that our model M 0 could predict next-three-year EA better than one-year). As well as the advantage of maintaining interpretability (a one-year EA probability was used in earlier versions of SPARRA) this target has the advantage of being independent of seasonal influences on EA frequency. Although a range of models have been proposed to predict EA, it is difficult to transfer information between geographic settings, since they are highly dependent on data collection protocols of healthcare systems [30]. We do not expect that our model will directly be used outside of Scotland. However, the design of our reproducible analysis pipeline is general and could be adapted to other settings. Performance of our model is weaker than that of a related model in England [25] , but this is unsurprising given reduced predictor availability in our study. In fact, data in [25] included primary care records and health indicators (body mass index, smoking status, laboratory tests). However, our model has the advantage of using only data routinely collected centrally at a national level by Scottish healthcare authorities (albeit not including records from GP practices), and can thus be computed for the general Scottish population without the need for any additional data collection. As for any predictive model in this area, the question of of translation into clinical action in a way which optimally benefits the patient is a vital area of ongoing research, and is essential for quantifying the benefit of including such scores in clinical practice. To do this, EA risk scores must be comprehensive, accurate, and interpretable, which we have aimed for in SPARRA v4. The SPARRA v4 model will be deployed in the Scottish NHS, augmenting the SPARRA v3 model. We expect that the SPARRA score will be most useful to patients for whom anticipatory care plans are not already in place, and for whom GPs do not know well. For this reason, well calibrated risk scores are particularly important. We anticipate that the SPARRA v4 tool will contribute to the overall effectiveness of the Scottish NHS, and correspondingly to the health of the Scottish population. We will collaborate to achieve a successful deployment and will carefully consider the feedback from GPs to improve the model and the communication of its results further (e.g. via informative dashboards). Ongoing work will evaluate the use of different target variable types, new machine learning methods, improved coverage of the Scottish population (SPARRA v4 only covers around 80% of the population and likely excludes healthy individuals with low engagement with the healthcare system), and translation to clinical action. As the COVID-19 pandemic resolves, it will also be important to assess potential effects of dataset shift [28], e.g. due to disproportionate mortality burden in older individuals and long term consequences of COVID-19 infections. We anticipate that robust and reproducible development of risk prediction scores such as SPARRA v4 will play an important role in the design of proactive interventions to manage future risk. 5 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. [23] . This precedes our cohort by three years. 6 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . Stratified performance of SPARRA v3 and v4. Panels 3a, 3b and 3c show difference in AUROC between v3 and v4 (red/black) and EA frequency (dashed lines) in subcohorts defined by age, SIMD and the original subcohorts defined during SPARRA v3 development (see Introduction), respectively. Panels 3d and 3e show SPARRA v4 performance by category of disease by ICD10 code (Abnormality NEC: abnormality not elsewhere classified; ). In panel 3d, bar height for a given particular x-axis category and a given colour (score threshold) is the proportion of individuals with EA reaching that score threshold admitted for that reason. Percentages sum to 100% across bars of each colour (score category) rather than disease category. A rising profile indicates relatively better prediction of this category. Panel 3e shows distribution of log-scores for individuals admitted in each class, with black points indicating the associated medians. Supplementary figure 11 shows equivalent data to panel 3d as positive-predictive values. Panel 3f shows the distribution of time-to-event after the first time cutoff amongst cohorts of individuals who 1) had an EA in the year following the time cutoff and 2) had a SPARRA v4 score above a given cutoff. Panel 3g shows the discrete distribution of number of events over the same cohorts. Panel 3h shows the distribution of time-to-event amongst cohorts of individuals who were admitted exactly once in the year following the first time cutoff. 8 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. show performance of static predictions made for the early time point at estimating risk for later time points. Lower panels for ROC curves show differences between sensitivity at t i and at t 1 ; for PRC curves difference in PPV between t i and t 1 ; and for calibration curves the difference between observed and expected EA frequency. Pointwise 95% confidence intervals for calibration curves are shown only for the final time point for clarity. Panel 4d shows the change in distribution centiles (light blue) and deciles (dark blue) of risk scores with time, across all individuals with data available at all time points. Panel 4e considers cohorts of individual by risk centiles (light blue) and deciles (dark blue) at the first time point (2 May 2015) and tracks average risks of these cohorts over time. Panel 4f shows joint density (low to high: white-grey-red-yellow) of individual risk scores at t 1 (2 May 2015) and t 2 (1 Dec 2015). The density is normalised to uniform marginal on the Y axis, then the X axis; true marginal distributions of risk scores are shown alongside in grey. Figure 5 . Panels 5a, 5b and 13 show non-linear influence of age, SIMD, and number of previous elective (Elec.) and emergency (Em.) admissions on risk scores. Panel 5c shows the number of additional years of age needed to contribute as much to risk score as a SIMD 1-SIMD 10 difference. Panel 5d shows 'Effective ages' for each age: for an (age,SIMD) pair, the age at mean SIMD with the equivalent EA rate. Table 5e shows the 20 most important variables by mean absolute Shapley value (percentage scale). Importance can be interpreted as the average percent added or subtracted to risk score due to this factor. Also see supplementary table 2 and Supplementary Figures 14-20. 10 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. ; https://doi.org/10.1101/2021.08.06.21261593 doi: medRxiv preprint A typical entry in the source EHR tables (Supplementary Table 1 ) recorded a single interaction between an individual and NHS Scotland (e.g. hospitalisation), with each record comprising a unique identifier (ID) for the individual, the date on which the interaction was initiated (admission), the date it ended (discharge), and details of the interaction (diagnoses made, procedures performed). We generated input features by scanning source tables for records corresponding to each ID-time pair. For each individual, we considered all records from up to three years before the time cutoff. Most input predictors were similar to those used for SPARRAv3 [1] . See Supplementary Table 2 for a full list of predictors. In terms of demographics, we included age, sex, and SIMD decile (the latter serving to use using geographic-level deprivation as a proxy for individual-level deprivation). Other input predictors include counts of previous admissions (e.g. A&E admissions, drug-and-alcohol related admissions), and the amount of time spent in hospital (e.g. emergency bed days). Following findings in [25] , where possible, we also included predictors encoding time-since-last-event (e.g. days since last outpatient attendance). From community prescribing data, we used predictors encoding the number of prescriptions for various pre-specified types (e.g. respiratory), as well as the total number of different types of prescriptions, number of paid prescription items, and total amount spent on prescriptions. From data on long-term conditions, we evaluated recorded presence of a long term condition (eg. multiple sclerosis, epilepsy), the number of years since diagnosis of a range of long-term conditions (e.g. asthma), the total number of long-term conditions recorded, and the number of long-term conditions resulting in hospital admissions. In addition to the predictors listed above, we used a Latent Dirichlet Allocation (LDA)-based topic model [5] to derive more information from prescriptions and long-term condition data. We jointly modelled prescriptions and long-term conditions using 30 topics, considering samples as 'documents' and conditions/prescriptions as 'words'. We retained the map from documents to topic probabilities, and used derived topic probabilities as input variables for our model. Document to topic probability maps were fitted only to the training set of data, and applied to test set data when evaluating accuracy. A range of other predictors are known to influence EA. In particular, an English study found that marital and smoking status, blood test parameters and family histories were highly predictive [25] . However, these were not included in our data which only contains information that is routinely collected in secondary care. In addition, due to privacy considerations, we did not have access to geographic location data. We would expect that patterns of EA risk would vary between rural and urban areas of Scotland, and this variation may be substantial given the geographic diversity of the region. As well as being unable to use geographic location as a predictor, this precluded the use of a geographically separated test set [30] . We had little cause to believe in advance that any particular class of models would be best for this problem. Thus, we considered a range of model types. Rather than selecting and using only the best performing model, we chose an ensemble defined as an optimal linear combination of model outputs (L 1 -penalised regression) in a similar way to Van der Laan (2007) [29] . Compared to choosing only one model, this slightly increases the range of predictor functions which are able to be modelled, slightly improves prediction, and reduces reliance on behaviour of a single model type, at the cost of a small number of additional degrees of freedom. We monotonically transformed the ensemble predictor to improve calibration by inverting the empirical calibration function (see Supplementary note 3 for details). As part of the ensemble, we considered a variety of constituent (base) models. These include an artificial neural network (ANN) [17] , two random forests (RF) [17] (one shallow, of depth 20, and one deep, of depth 40), three gradient boosted trees (XGB) [8] (of maximum constituent tree depth 3,4, and 8), a generalised linear model (GLM) [17] , a naive Bayes model (NB) [17] , and the model used in SPARRA v3 (v3) [1] ). Full details of these models are given in the Supplementary Note 1. Since all non-primary care interactions with NHS Scotland are recorded in the input databases, there was no missingness for most predictors. For 'time-since-interaction' type predictors, individual-time pairs for which there was no recorded interaction were coded as the maximum lookback time. There was some missingness in SIMD records (∼0.7%), possibly due to individuals without a fixed address, and in topic features (∼0.8%). In both cases, missingness would be expected to be non-random and possibly informative. We thus managed predictor missingness in different ways across constituent models. We used mean-value imputation in the ANN and GLM models (deriving mean values from training data only), used missingness to inform tree splits (defaults in [17] ) in RF, used sample-wise imputation in XGB (as per [8] ) and dropped during fitting (default in [17] ) in NB (omitted missing values for prediction). We optimised various metrics for constituent models, which were generally the default in the relevant functions. For the ANN, RFs and GLM, we minimised log-loss; for the NB model, likelihood; and for the XGB trees, a logistic objective. For fitting model weights in the ensemble ensemble, we optimised area under an ROC curve (AUROC) as a metric for model fit. Although our primary endpoint for model performance was AUROC, we also considered area-under-precision-recall curve and calibration curves for visualisation of results. We plotted calibration curves using a kernelised calibration estimator; see Supplementary Note 5. We compared the performance of predictive models with and without topic features by evaluating AUROCs for prediction on a given year, and compared AUROCs using DeLong's test [11] . For simplicity, figures show ROC/PR curves for combined cross-validation folds (that is, given fold-wise predictionŝ and similarly for PR curves). Quoted AUROC/AUPRC values are means over folds (that is, 1 3 , which averts problems from between-fold differences in models [14] . For fairness of comparison, we also used mean-over-folds to compute quoted AUROCs and AUPRCs for SPARRA v3, although SPARRA v3 was not fitted to our data. We fitted and evaluated the model using three-fold cross-validation (see supplementary Figure 1 ). Each third of the data was used as a training, validation and test set in turn. The full dependency structure is shown in supplementary figure 1. For each fold, the prediction function used was independent of data in that fold. A full description of the cross-validation procedure is given in Supplementary note 3. Our aim in producing the SPARRA score is to produce an accurate estimate of EA risk in the coming year under normal medical care. In other words, the score should represent the true EA risk if the score was not visible to the GPs. Because GPs see the score and may act on it, the observed risk may be lower than predicted -the score may become a 'victim of its own success' [18, 27] . Unfortunately, since the SPARRA v3 score is universally available to GPs, and may be acted on, we cannot assess the behaviour of the medical system in its absence. As illustrated in [19] , this is potentially hazardous. Formally, at a given fixed time, for each individual, EA in the next 12 months is a Bernoulli random variable. The probability of the event for individual i is modelled conditional on a set of covariates X i derived from their EHR. We denote v3(X i ), v4(X i ) the derived SPARRA v3 and v4 scores as functions of covariates, and assume a causal structures shown in Figure 6 . With no SPARRA-like predictive score in place, there is only one causal pathway X i → EA ( Figure 6A ). It is to this system (coloured red) that v3 was fitted. In this setting, v3(X i ) is an estimator of the 'native' risk Pr(EA|X i ) (this ignores the effect of previous versions of the SPARRA score, which covered less than 30% of the Scottish population). Although v3(X i ) is determined entirely by X i , the act of calculating and distributing values of v3(X i ) to GPs opens a second causal pathway from X i to EA ( Figure 6B ). This is driven by GP interventions made in response to v3(X i ) scores. It is to this system (coloured red) that SPARRA v4 is fitted. Hence, v4(X i ) is an estimator of Pr(EA|X i , v3(X i )), a 'conditional' risk after interventions driven by v3(X i ) have been implemented. If v4 naively replaced v3 ( Figure 6C ), we would be using v4 to predict behaviour of a system different to that on which it was trained ( Figure 6B ). To amend this problem, we propose to use v4 in conjunction with v3 rather than to replace it ( Figure 6D ). Ideally, GPs would be given v3(X i ) and v4(X i ) simultaneously and asked to firstly observe and act on v3(X i ), then observe and act on v4(X i ), thereby only using v4(X i ) as per Figure 6D . This is impractical, so instead, we disseminate to GPs the single value max(v3, v4), avoiding the potential hazard of risk underestimation, at the cost of loss of score calibration. Raw data for this project are patient-level NHS Scotland health records, and are confidential. Due to the confidential nature of the data used, all analysis took place on remote 'safe havens' [2, 4] , without access to internet, software updates or unpublished software. Information Governance training was required for all researchers accessing the analysis environment. Moreover, to avoid the risk of accidental disclosure of sensitive information, an independent team carried out statistical disclosure control checks to all data exports, including the outputs presented in this manuscript. All analysis code and co-ordinates required to reproduce our Figures are available in github.com/jamesliley/SPARRAv4. This work was conducted in accordance with UK data governance regulations under PBPP application number eDRIS 1718-0370 12 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. ; https://doi.org/10.1101/2021.08.06.21261593 doi: medRxiv preprint Figure 6 . Causal structure for fitting of SPARRA v3 and v4. X i represents covariates for a patient-time pair; Y represents the EA event; v3( f it)/v4( f it) and v3(X i )/v3(X i ) represent the fitting and deployment of v3 and v4 respectively. Note v3 and v4 are fitted to different systems, so v4 cannot be used to directly replace v3. [24] World Health Organization. International statistical classification of diseases and related health problems. [28] Adarsh Subbaswamy and Suchi Saria. "From development to deployment: dataset shift, causality, and shift-stable models in health AI". In: Biostatistics 21.2 (2020), pp. 345-352. [29] Mark J Van der Laan, Eric C Polley, and Alan E Hubbard. "Super learner". In: Statistical applications in genetics and molecular biology 6.1 (2007). [30] Emma Wallace et al. "Risk prediction models to predict emergency hospital admission in community-dwelling adults: a systematic review". In: Medical care 52.8 (2014), p. 751. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 3 : Areas under ROC/PRC curves for each constituent model by cross-validation fold 4. Table 4 : Exploration of contributors to each topic. 5. Figure 29. TRIPOD: Checklist for TRIPOD guidelines [11] , and associated pages. S1 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. ; https://doi.org/10.1101/2021.08.06.21261593 doi: medRxiv preprint Reference Description Notes SMR00 [4] Outpatient attendance SMR01 [5] Acute hospital admissions Non-psychiatric, non-obstetric SMR01E [6] Geriatric long stay SMR04 [5] Psychiatric hospital admissions Acute only AE2 [1] Accident and emergency records PIS [3] Prescribing information SystemWatch [7] Urgent care monitoring LTC [2] Long-term conditions Table 1 . Data sources used to derive SPARRA v4 predictors. SMR -Scottish Morbidity Records. Also see Figure 1b S2 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 4 . Details of derived topics for topic model used for prediction in fold 1 (fitted to folds 2 and 3). A topic model assumes that each 'document' (individual) in a 'corpus' (population) is associated with various 'topics' (roughly, illness categories) where each topic corresponds to a distribution over 'words' (ICD10 codes and medication types). We would expect that the 30 topics fitted to each fold roughly represent the major clusters of disease types which occur amongst those individuals. This tables shows the 'words' with the highest probability of membership in each topic (> 1%, where probabilities over all words sum to 100%). In each topic, words are ordered by decreasing probability of topic membership. ICD10 codes are italicised; medication types are not. Topics are ordered by decreasing importance (mean absolute Shapley value). We assign labels to some topics which appear to code for clear disease types, italicised for tenuous links. S11 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. Pr % % / ⫫ % | % "$ 6 ⫫ % , % Figure 1 . Variable dependencies. Boxes denote random variables, arrows denote causal dependence. In general, X · are predictors, Y · are targets, T · is a topic model, β · are parameters, and λ · are hyperparameters. See online methods for details. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. . Joint density (low to high: white-grey-red-yellow) of individual risk scores at t i and t j for (i, j) ∈ {1, 2, 3, 4, 5}, i < j. The density is normalised to uniform marginals; true marginal distributions of risk scores are shown alongside in grey. S18 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. Figure 10 . SPARRA v4 performance by category of admission type. Bar height for a given particular x-axis category and a given colour indicates the number of individuals with that x-axis category as a proportion of the cohort of individuals reaching the SPARRA v4 threshold indicated by the colour; note that percentages sum to 100 across bars of each colour, not each category. For a given x-axis category, a rising profile for greyer colours indicates relatively better prediction of this category and a dropping profile indicates worse prediction. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. Figure 11 . SPARRA v4 performance by type of admission; data as per figure 3d. Bar height for a given particular x-axis category and a given colour indicates the positive predictive value for predicting an admission of that type given a score ≥ the associated value. Note that, particularly for low scores, the positive predictive value for being admitted at all is low. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. ; https://doi.org/10.1101/2021.08.06.21261593 doi: medRxiv preprint SUPPLEMENTARY NOTE We used a range of constituent models, detailed below. In all cases, hyperparameters were determined by randomly splitting the relevant dataset into a training and test set of 80% and 20% of the data respectively. We used SPARRA v3 as one constituent model. We used an artificial neural network as implemented in the h2o platform (via the h2o R package [13] ). We optimised over the number of layers (1 or 2) and the number of nodes in each layer (128 or 256). We used a training dropout rate of 20% to reduce generalisation error. We fitted two random forests using the h2o R package [13] . One had maximum depth 20 and 500 trees, and the other had maximum depth 40 and 50 trees (both taking a similar time to fit). Settings were otherwise left as h2o defaults (see [13] ). We used the R package xgboost [10] to fit three boosted tree models, considering the number of trees as a hyperparameter. We considered trees at three maximum depths: 3, 4, and 8. For the deeper-tree model, we set a low step size shrinkage (η) of 0.075 and a positive minimum loss reduction (γ) of 5 in order to avoid overfitting. In the other two models, we used default values of η=0.3, γ = 0. We used the h2o package [13] to fit naive Bayes models. The only hyperparameter we considered was a Laplace smoothing parameter, varying between 0 and 4. We used the h2o package [13] to fit generalised linear models. We optimised L 1 and L 2 penalties (an elastic net), considering total penalty (L 1 + L 2 ) in 10 −{1,2,3,4,5} , and a ratio L 1 /L 2 in {0, 0.5, 1}. We aggregated models by finding the linear combination which optimised AUROC in a separate training sample. We included an L 1 penalty as a hyperparameter in this step [12] . A problem in choice or target arises due to death of individuals during the follow-up year. Broadly, there are four options for how to treat such individuals: 1. Exclude them from the dataset 2. Classify them as according to whether they had an emergency admission before they died 3. Classify them as no admission, or The philosophy of the SPARRA score is to avert breakdowns in health, of which death can be considered an example. Option 3 would effectively classify death as a 'desirable' outcome, so we avoided it. Option 2 would effectively mean such individuals have a follow-up time less than a year, and would classify individuals who died without a hospital admission as having had a 'desirable' outcome. Option 1 would exclude the most critically ill individuals from the dataset. Our choice of option 4 allows the general description of the target as 'a catastrophic breakdown in health'. It would also be possible to code death in follow-up differentially; for instance, coding in-hospital death as EA and in-community death as exclusions or non-EA. Our choice not to code all deaths identically is in the interests of non-maleficence. If an individual is at risk of imminent death in the community they will typically be admitted to hospital if it is possible to react in time, with a possible exemption if this is not in their best interests. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. ; https://doi.org/10.1101/2021.08.06.21261593 doi: medRxiv preprint The error in SPARRA scores from coding all deaths as EA is thus in assigning high scores to the very old and terminally ill, when in fact these individuals may be treated in the community rather than admitted. The potential harm from this option is small: it could mean that such individuals are excessively treated rather than palliated, but since palliation over treatment is an active decision [14] and such individuals are generally known to be high-risk it is unlikely that the SPARRA score will adversely affect any decisions in this case. However, the error from coding community deaths as non-EA would be more severe, as it could mean that healthier individuals at risk of sudden death are either coded as non-EA or excluded from the dataset, potentially leading to inappropriately low scores being assigned to these individuals. This could draw treatment away from individuals in high need. Denote by For prediction on fold 3, we began by fitting a Latent Dirichlet Allocation-based topic model T 12 to predictor data (X 1 , X 2 ), retaining 30 topic features to be used as predictors. See [8] for details. For each constituent model F i we partitioned X 1 , Y 1 into train/test sets in size ratio 4 : 1 and determined fold-specific parameters {β 1 } i and hyperparameters {λ 1 } i in the usual way according to We then evaluated each model on X 2 and established an optimal L-1 penalised linear sum with parameters β e 12 and hyperparameter λ e 12 (e for 'ensemble'), after splitting into cross-validation folds: where bars indicate mean over each cross-validation permuation of train/test sets. Given the output of the ensembleỸ 2 (X 2 ) = β e ·Ŷ 2 (taken as a function of X 2 ), we then computed a transform m e 12 (x) to optimise calibration, essentially using isotonic regression. We defined an empirical calibration function for an estimator Y (X) of Y |X: All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. ; https://doi.org/10.1101/2021.08.06.21261593 doi: medRxiv preprint We first found a, b such that the mean and mode of (aỸ 2 + b) were approximately correctly calibrated; that is, CAL aỸ 2 +b (x) = x for x ∈ {mean(aỸ 2 + b), mode(aỸ 2 + b)}, and scaled a, b such that 0 ≤ aỸ 2 (X 2 ) + b ≤ 1. Across an evenly spaced grid G of 100 x-values we computed the function: c(x) = (1 − 10 −5 ) max x ∈G;x ≤x CAL aỸ 2 +b (x ) + 10 −5 x (3) using the cumulative maximum of CAL(x) to ensure c is non-decreasing, and adding a linear term to ensure c is increasing. We extended the domain of c to [0, 1] using piecewise linear interpolation, and defined our calibrating transform m e 12 as the inverse of c: Finally, we re-determined parameters and hyperparameters on folds 1 and 2 (denoting X 12 = (X 1 , X 2 ), Y 12 = (Y 1 ,Y 2 ) β max (λ ) arg min β ∈B i L i F i X train 12 , T 12 (X train 12 ); β , λ ,Y train Considered as a function of X, this function depends only on parameters determined using X 12 , Y 12 , and hence is independent of X 3 and Y 3 and conditionally independent of Y 3 given X 3 . Data study groups (DSGs) are week long collaborative efforts held in the Alan Turing Institute, where teams of students, early career researchers in data science combine to tackle the real-world problems of non-academic partners. In 2017, one such event was organised with the task of exploring the scope of improving SPARRA performance using modern approaches in machine learning. Despite the time restrictions of this project, results were promising, suggesting advanced machine learning techniques such as random forests offered improved performance over traditional approaches such as logistic regression, as used in the SPARRA v3 model. This project arose from a collaboration between Public Health Scotland, the Scottish National Health Service, and the Alan Turing Institute, a UK government-founded artificial intelligence research organisation. Collaboration between groups was largely electronic, but face-to-face knowledge transfer meetings were essential in facilitating knowledge transfer between groups. We assume in general that, for IID predictor/outcome pairs (X i ,Y i ) ∼ (X,Y ), i ∈ 1..n, and an optimal predictor function p opt , we have noting that this implies p opt (X) = E[Y |p opt (X)] We want to estimate p opt (X). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. ; (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. 13 TRIPOD guidelines and pages where discussed All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. ; https://doi.org/10.1101/2021.08.06.21261593 doi: medRxiv preprint A Report on the Development of SPARRA Version 3 (Developing Risk Prediction to Support Preventative and Anticipatory Care in Scotland The National framework for service change in NHS Scotland Design choices for productive, secure, data-intensive research at scale in the cloud Latent Dirichlet allocation Focus on preventable admissions Identifying patients at high risk of emergency hospital admissions: a logistic regression analysis Extreme Gradient Boosting Alternatives to hospital care: what are they and who should decide? Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) The TRIPOD Statement Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Demographic and practice factors predicting repeated non-attendance in primary care: a national retrospective cohort analysis Scottish index of multiple deprivation 2006 technical report Apples-to-apples in cross-validation studies: pitfalls in classifier performance measurement Scottish index of multiple deprivation Risk prediction models for hospital readmission: a systematic review Prognostic models will be victims of their own success, unless Model updating after interventions paradoxically introduces bias A unified approach to interpreting model predictions Predicting the likelihood of emergency admission to hospital of older people: development and validation of the Emergency Admission Risk Likelihood Index (EARLI) Measuring appropriate use of acute beds: a systematic review of methods and results Census aggregate data Since we only observe Y = 1 or Y = 0, we must estimate E[Y |p(X) = z] as some kind of average of Y about observed values p(X) close to z. A routine way to do this is to use 'reliability diagrams' [9] in which we bin values of p(X) and estimate E(Y |p(X)) in each bin. Since for small bin sizes there may be few or no values of p(X) in some bins, we use a kernel estimateĉ p (z) of REFERENCES [1 Public health information Scotland PIS -prescribing information systems Public health information Scotland Public health information Scotland SMR01 -Acute Hospital Admissions; SMR04 -Psychiatric Hospital Admissions Public health information Scotland Latent Dirichlet allocation Increasing the reliability of reliability diagrams Extreme Gradient Boosting Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) The TRIPOD Statement Regularization paths for generalized linear models via coordinate descent The authors note that this project's success was entirely contingent on close co-operation between the Alan Turing Institute (JL, GB, NC, SV, LA, CV) and Public Health Scotland (RP, JI, DC, KB, SH, KP, SO, SR). We thank all individuals involved in primary care in Scotland for the continued support of the SPARRA project, as well as the general Scottish population.Authorial contributions were as follows: In all plots in this paper, we bounded bias under the assumption that there existed k such that |c p (z) − kz| < z 2 /10.The calibration estimator derived here is demonstrated in an R script sparra calibration.R available with the attached R code for this manuscript.